Roxadustat use was associated with a lower risk of bleeding and thromboembolic events in CKD patients on hemodialysis. This association may be mediated through the stabilization of hemoglobin levels, modulation of iron metabolism, and attenuation of inflammation.
Man et al. (Wed,) studied this question.